

# Protocol for the Examination of Specimens From Patients With Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis

Protocol applies to all malignant germ cell and sex cord-stromal tumors of the testis. Paratesticular malignancies are excluded.

---

Based on AJCC/UICC TNM, 7th edition

Protocol web posting date: October 2013

## Procedures

- Radical Orchiectomy
- Retroperitoneal Lymphadenectomy (RPLND)

## Authors

Satish K. Tickoo, MD\*

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY

Victor E. Reuter, MD

Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY

Mahul B. Amin, MD, FCAP

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California

Sam S. Chang, MD

Department of Urologic Surgery, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Peter A. Humphrey, MD, PhD, FCAP

Department of Pathology and Immunology, Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, Missouri

James McKiernan MD

Department of Urology, Columbia University NY, NY

John R. Srigley, MD, FCAP

Department of Laboratory Medicine, Credit Valley Hospital, Mississauga, Ontario, Canada

Thomas M. Ulbright, MD

Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana

Ming Zhou, MD, PhD, FCAP†

Department of Pathology, New York University Langone Medical Center, New York, NY

For the Members of the Cancer Committee, College of American Pathologists

\* Denotes primary author. † Denotes senior author. All other contributing authors are listed alphabetically.

**Previous contributors:** Richard S. Foster, MD; Patrick J. Loehrer, MD; Judd W. Moul, MD; Jae Y. Ro, MD; Robert E. Scully, MD; Gillian M. Thomas, MD

© 2013 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from the CAP.

Any public dissemination of the original or modified protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.

## CAP Testis Protocol Revision History

---

### Version Code

The definition of the version code can be found at [www.cap.org/cancerprotocols](http://www.cap.org/cancerprotocols).

**Version:** Testis 3.3.0.0

### Summary of Changes

The following changes have been made since the June 2012 release.

### Radical Orchiectomy

#### Tumor Size

"Required only if applicable" was added to "Greatest dimensions of additional tumor nodules."

**Macroscopic Extent of Tumor (select all that apply):** "Cannot be assessed" was added.

**Microscopic Extent of Tumor (select all that apply):** "Cannot be assessed" was added.

**Microscopic Tumor Extension (select all that apply):** "Not identified" was added.

#### Regional Lymph Nodes (pN)

Updated the definitions of pN1, pN2, and pN3 as follows:

- pN1: Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to 5 nodes positive, none more than 2 cm in greatest dimension
- pN2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor
- pN3: Metastasis with a lymph node mass more than 5 cm in greatest dimension

Added: "If lymph nodes involved, specify histologic subtype: \_\_\_\_\_."

**Additional Pathologic Findings:** "Intratubular germ cell neoplasia" was deleted.

### Retroperitoneal Lymphadenectomy

#### Size of Largest Metastatic Deposit in Lymph Node

Changed unit of measure from centimeters (cm) to millimeters (mm).

**Histologic Viability of Tumor (if applicable):** Added "(select all that apply)."

#### Regional Lymph Nodes (pN)

Updated the definitions of pN1, pN2, and pN3 as follows:

- pN1: Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to 5 nodes positive, none more than 2 cm in greatest dimension
- pN2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor
- pN3: Metastasis with a lymph node mass more than 5 cm in greatest dimension

## Surgical Pathology Cancer Case Summary

---

Protocol web posting date: October 2013

### TESTIS: Radical Orchiectomy

Select a single response unless otherwise indicated.

#### Specimen Laterality

- Right  
 Left  
 Not specified

#### Tumor Focality

- Unifocal  
 Multifocal

#### Tumor Size

Greatest dimension of main tumor mass: \_\_\_ cm

+ Additional dimensions: \_\_\_ x \_\_\_ cm

Greatest dimensions of additional tumor nodules (required only if applicable): \_\_\_ cm, \_\_\_ cm, etc

Cannot be determined (see Comment)

#### Macroscopic Extent of Tumor (select all that apply)

- Confined to the testis  
 Invades hilar soft tissues  
 Invades tunica vaginalis (perforates mesothelium)  
 Invades epididymis  
 Invades spermatic cord  
 Other (specify): \_\_\_\_\_  
 Cannot be assessed

#### Histologic Type (select all that apply) (Notes A and B)

- Intratubular germ cell neoplasia, unclassified only  
 Seminoma, classic type  
 Seminoma with associated scar (Note C)  
 Seminoma with syncytiotrophoblastic cells  
 Mixed germ cell tumor (specify components and approximate percentages):  
 \_\_\_\_\_  
 \_\_\_\_\_

- Embryonal carcinoma  
 Yolk sac tumor  
 Choriocarcinoma, biphasic  
 Choriocarcinoma, monophasic  
 Placental site trophoblastic tumor  
 Teratoma  
 Teratoma with a secondary somatic-type malignant component  
 (specify type): \_\_\_\_\_  
 Monodermal teratoma, carcinoid  
 Monodermal teratoma, primitive neuroectodermal tumor  
 Monodermal teratoma, other (specify): \_\_\_\_\_

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

- Spermatocytic seminoma  
 Spermatocytic seminoma with a sarcomatous component  
 Mixed germ cell-sex cord-stromal tumor, gonadoblastoma  
 Mixed germ cell-sex cord-stromal tumor, others  
 (specify): \_\_\_\_\_  
 Testicular scar (Note C)  
 Scar only  
 Scar with intratubular germ cell neoplasia  
 Sex cord-stromal tumor  
 Leydig cell tumor  
 Sertoli cell tumor  
 Classic  
 Sclerosing  
 Large cell calcifying  
 Granulosa cell tumor  
 Adult-type  
 Juvenile-type  
 Mixed, with components (specify components and approximate percentages):  
 \_\_\_\_\_  
 \_\_\_\_\_  
 Unclassified  
 Malignant neoplasm, type cannot be determined  
 Other (specify): \_\_\_\_\_

### Margins

#### Spermatic Cord Margin

- Cannot be assessed  
 Involved by tumor  
 Uninvolved by tumor

#### Other Margin(s)

- Cannot be assessed  
 Involved by tumor (specify): \_\_\_\_\_  
 Uninvolved by tumor (specify): \_\_\_\_\_  
 Not applicable

### Microscopic Tumor Extension (select all that apply) (Note D)

- Rete testis  
 Epididymis  
 Hilar fat  
 Spermatic cord  
 Tunica vaginalis (perforates mesothelium)  
 Scrotal wall  
 Other (specify): \_\_\_\_\_  
 Cannot be assessed  
 Not identified

### Lymph-Vascular Invasion (Note E)

- Absent  
 Present  
 Indeterminate

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

**Pathologic Staging (pTNM) (Note F)**TNM Descriptors (required only if applicable) (select all that apply)

- m (multiple)  
 r (recurrent)  
 y (posttreatment)

Primary Tumor (pT)

- pTX: Cannot be assessed  
 pT0: No evidence of primary tumor  
 pTis: Intratubular germ cell neoplasia (carcinoma in situ)  
 pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade tunica albuginea but not tunica vaginalis  
 pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis  
 pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion  
 pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed  
 pN0: No regional lymph node metastasis  
 pN1: Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to 5 nodes positive, none more than 2 cm in greatest dimension  
 pN2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor  
 pN3: Metastasis with a lymph node mass more than 5 cm in greatest dimension  
 No nodes submitted or found

*Number of Lymph Nodes Examined*

- Specify: \_\_\_\_\_  
 Number cannot be determined (explain): \_\_\_\_\_

*Number of Lymph Nodes Involved*

- Specify: \_\_\_\_\_  
 Number cannot be determined (explain): \_\_\_\_\_

If lymph nodes involved, specify histologic subtype: \_\_\_\_\_

Distant Metastasis (pM)

- Not applicable  
 pM1: Distant metastasis present  
 pM1a: Nonregional nodal or pulmonary metastasis  
 pM1b: Distant metastasis other than to nonregional lymph nodes and lung  
     + Specify site(s), if known: \_\_\_\_\_

**+ Pre-Orchiectomy Serum Tumor Markers (select all that apply) (Notes F and G)**

- +  Unknown
- +  Serum marker studies within normal limits
- +  Alpha-fetoprotein (AFP) elevation
- +  Beta subunit of human chorionic gonadotropin (b-hCG) elevation
- +  Lactate dehydrogenase (LDH) elevation

**+ Post-Orchiectomy Serum Tumor Markers (select all that apply) (Notes F and G)**

- +  Unknown
- +  Serum marker studies within normal limits
- +  Alpha-fetoprotein (AFP) elevation
- +  Beta subunit of human chorionic gonadotropin (b-hCG) elevation
- +  Lactate dehydrogenase (LDH) elevation

**+ Serum Tumor Markers (S) (Note G)**

- +  SX: Serum marker studies not available or performed
  - +  S0: Serum marker study levels within normal limits
- |                                | <u>LDH</u>            | and | <u>HCG (mIU/mL)</u> | and | <u>AFP (ng/mL)</u> |
|--------------------------------|-----------------------|-----|---------------------|-----|--------------------|
| + <input type="checkbox"/> S1: | <1.5 X N <sup>#</sup> |     | <5,000              |     | <1,000             |
| + <input type="checkbox"/> S2: | 1.5-10 X N            | or  | 5,000-50,000        | or  | 1,000-10,000       |
| + <input type="checkbox"/> S3: | >10 X N               | or  | >50,000             | or  | >10,000            |

*# N indicates the upper limit of normal for the LDH assay.*

**+ Additional Pathologic Findings (select all that apply) (Note H)**

- +  None identified
- +  Hemosiderin-laden macrophages
- +  Atrophy
- +  Other (specify): \_\_\_\_\_

**+ Comment(s)**

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.

## Surgical Pathology Cancer Case Summary

---

Protocol web posting date: October 2013

### TESTIS: Retroperitoneal Lymphadenectomy (Note A)

Select a single response unless otherwise indicated.

#### + Prelymphadenectomy Treatment

- +  Chemo/radiation therapy
- +  No chemo/radiation therapy
- +  Unknown

#### + Serum Tumor Markers (select all that apply) (Note G)

- +  Unknown
- +  Serum marker studies within normal limits
- +  Alpha-fetoprotein (AFP) elevation
- +  Beta subunit of human chorionic gonadotropin (b-hCG) elevation
- +  Lactate dehydrogenase (LDH) elevation

#### + Specimen Site(s)

+ Specify: \_\_\_\_\_

#### + Number of Nodal Groups Present

- + Specify:
- +  Cannot be determined

#### Size of Largest Metastatic Deposit in Lymph Node

Greatest dimension:  mm

+ Additional dimensions:  x  mm

#### Histologic Viability of Tumor (if applicable) (select all that apply)

- Viable teratoma present
- Viable nonteratomatous tumor present
- No viable tumor present

#### Histologic Type of Metastatic Tumor (Note B)

- Seminoma, classic type
- Seminoma with syncytiotrophoblastic cells
- Mixed germ cell tumor (specify components and approximate percentages):

\_\_\_\_\_

- Embryonal carcinoma
- Yolk sac tumor
- Choriocarcinoma, biphasic
- Choriocarcinoma, monophasic
- Cystic trophoblastic tumor
- Placental site trophoblastic tumor
- Teratoma
- Teratoma with a secondary somatic-type malignant component  
(specify type): \_\_\_\_\_

+ Data elements preceded by this symbol are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management.



- Monodermal teratoma (specify type): \_\_\_\_\_  
 Spermatocytic seminoma  
 Spermatocytic seminoma with a sarcomatous component  
 Malignant neoplasm, type cannot be determined  
 Other (specify): \_\_\_\_\_

**Regional Lymph Nodes (pN) (Note I)**

- pNX: Cannot be assessed  
 pN0: No regional lymph node metastasis  
 pN1: Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to 5 nodes positive, none more than 2 cm in greatest dimension  
 pN2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor  
 pN3: Metastasis in a lymph node more than 5 cm in greatest dimension  
  
 No nodes submitted or found

Number of Lymph Nodes Examined

- Specify: \_\_\_\_\_  
 Number cannot be determined (explain): \_\_\_\_\_

Number of Lymph Nodes Involved

- Specify: \_\_\_\_\_  
 Number cannot be determined (explain): \_\_\_\_\_

**Nonregional Lymph Node Metastasis (M1a) (Note I)**

- Not applicable  
 Not identified  
 Present

**+ Comment(s)**

## Explanatory Notes

---

### A. Tissues Submitted for Microscopic Evaluation

The entire testicular tumor may be blocked if it requires 10 blocks or less (tissue may be retained for special studies); 10 blocks of larger tumors may be taken, unless the tumor is greater than 10 cm, in which case 1 block may be submitted for every 1 cm of maximum tumor dimension. Blocks must contain the interface with nontumorous testis, as well as the tunica albuginea, even away from the tumor, because lymphatic invasion is best appreciated in the peritumoral tissue, as well as in the vessels within and under/parallel to the tunica. Tissues to be sampled include:

- Tumor, including interface with surrounding testis, and tunica albuginea
- All of the grossly different appearing areas in the tumor
- Testicular hilum/mediastinum testis
- Uninvolved testis, including tunica albuginea
- Epididymis
- Spermatic cord, including cord margin
- Other lesion(s)
- All identifiable lymph nodes<sup>#</sup>
- Other tissue(s) submitted with specimen

<sup>#</sup> For large masses which have obliterated individual nodes, 1 section for every centimeter of maximum tumor dimension, including grossly different looking areas, should be taken.

The margins in a specimen resected for a malignant tumor of the testis, depending on the extent of the surgery, include spermatic cord margin, the parietal layer of tunica vaginalis, and scrotal skin.

### B. Histologic Type

The protocol mainly applies to malignant tumors of the testis, the vast majority of which are of germ cell origin. It may also be applied to other malignant or potentially malignant tumors of the testis included in the classification shown below.<sup>1-12</sup> For lymphomas and plasmacytomas of the testis, refer to the CAP non-Hodgkin lymphoma protocol.

### Modified Armed Forces Institute of Pathology (AFIP) and World Health Organization (WHO) Histologic Classification of Testicular Tumors

#### Germ Cell Tumors

##### Precursor lesion

- Intratubular germ cell neoplasm, unclassified
- Intratubular germ cell neoplasm, specific type

##### Tumors of 1 histologic type

###### Seminoma

- Variant: Seminoma with syncytiotrophoblastic cells
- Partially regressed tumor showing seminoma with scar

###### Spermatocytic seminoma

- Variant: Spermatocytic seminoma with a sarcomatous component

###### Embryonal carcinoma

###### Yolk sac tumor

###### Choriocarcinoma

- Variant: "Monophasic" type

###### Placental site trophoblastic tumor

###### Trophoblastic tumor, unclassified

## Teratoma

- With a secondary somatic-type malignant component

- Monodermal variants

- Carcinoid

- Primitive neuroectodermal tumor

- Others

- Tumors of more than 1 histologic type

- Mixed germ cell tumor (specify components; estimate approximate percentage of each)

- Testicular scar, consistent with regressed tumor

- Scar only

- Scar with intratubular germ cell neoplasia

- Partially regressed tumor with scar and residual germ cell tumor (specify type)

Sex Cord-Stromal Tumors

- Leydig cell tumor

- Sertoli cell tumor

- Variant: Large cell calcifying Sertoli cell tumor

- Variant: Sclerosing Sertoli cell tumor

- Granulosa cell tumor

- Adult type

- Juvenile type

- Mixed and indeterminate (unclassified) sex cord stromal tumor

Mixed Germ Cell- Sex Cord-Stromal Tumors

- Gonadoblastoma

- Unclassified

Miscellaneous

- Sarcoma (specify type)

- Plasmacytoma

- Lymphoma (specify type)

- Granulocytic sarcoma or leukemic infiltrates

- Adenocarcinoma of rete testis

- Carcinomas and borderline tumors of ovarian type

- Malignant mesothelioma


**C. Scar**

Testicular scars, particularly in patients presenting with metastatic disease and clinically inapparent testicular primaries, may represent regressed, "burnt-out" testicular germ cell tumors. Features that further favor such a diagnosis include associated intratubular calcifications, intratubular germ cell neoplasia unclassified (IGCNU), a lymphoplasmacytic infiltrate, hemosiderin-containing macrophages, and testicular atrophy. Scars with residual invasive tumors most likely represent partial regression of the tumor. In otherwise pure seminoma, such partial regression may have clinically important implications, since it is possible that some of these scars may represent regression of a nonseminomatous germ cell tumor component of the tumor.

**D. Invasion of the Rete Testis, Hilar/Mediastinal Soft Tissue, Epididymis or Tunica Vaginalis**

Tumors invading the tunica vaginalis (perforating the mesothelial lining) (Figure 1, Tumor A) are considered as stage pT2 by the American Joint Committee on Cancer (AJCC) TNM staging system. Invasion of rete testis or epididymis is not assigned a higher pT stage than that for a tumor limited to the testis. Rete testis invasion has been reported by some to be associated with higher risk of relapse in clinical stage I seminoma.<sup>13</sup> Hilar soft tissue invasion (Figure 1, Tumor B) is the predominant pathway of

extratesticular extension for testicular tumors.<sup>14</sup> However, the issue of hilar soft tissue invasion has not been addressed by AJCC TNM, and its clinical significance also has not been studied well.



**Figure 1.** Diagrammatic representation of a tumor (Tumor A) invading tunica vaginalis, perforating through the mesothelium, and another tumor (Tumor B) partly involving the rete testis and invading the hilar soft tissue. Figure courtesy of Safish K. Tickoo, MD.

### E. Venous/Lymphatic Vessel Invasion

In several studies, the presence of vascular space invasion (usually lymphatic but possibly also capillary or venous invasion) has been correlated with a significantly elevated risk for distant metastasis.<sup>15-21</sup> This observation, therefore, is most pertinent for patients who have clinical stage I disease, ie, those who have no evidence of spread beyond the testis by clinical examination (including radiographic and serum marker studies). Some clinicians manage the patients with clinical stage I disease who lack evidence of lymphatic or vascular invasion in their orchiectomy specimens (with possibly other favorable prognostic features, such as relatively small amounts of embryonal carcinoma) by close follow-up examinations rather than intervention.

The AJCC TNM staging system does not specifically address the issue of vascular invasion in the spermatic cord. While invasion of the cord is considered a pT3 stage, it would be logical to regard vascular invasion in the cord as pT2 stage, unless the tumor penetrates through the vessel wall into perivascular soft tissues of the cord.

### F. Staging

The protocol recommends staging according to the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) TNM staging system.<sup>23,24</sup> Additional criteria for staging seminomas according to a modification of the Royal Marsden system are also recommended.<sup>24</sup> Some studies suggest that the staging of patients with seminoma by the TNM system is less meaningful therapeutically than staging by a modification of the Royal Marsden method.<sup>22-24</sup> Also, the data from a large Danish study of seminomas clinically limited to the testis do not support the conclusion that local staging of the primary tumor, as performed in the TNM system, provides useful prognostic information; rather, the most valuable prognostic indicator was the size of the seminoma.<sup>25</sup> This protocol, therefore,

encourages the use of the TNM system with optional use of the modified Royal Marsden staging system for patients with seminoma.

### AJCC/UICC TNM and Stage Groupings

By AJCC/UICC convention, the designation "T" refers to a primary tumor that has not been previously treated. The symbol "p" refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

### TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The "m" suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The "y" prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The "r" prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the "r" prefix: rTNM.

The "a" prefix designates the stage determined at autopsy: aTNM.

### Additional Descriptors

#### Residual Tumor (R)

Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

RX	Presence of residual tumor cannot be assessed
R0	No residual tumor
R1	Microscopic residual tumor
R2	Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of

the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

### Modified Royal Marsden Staging System

Stage I	Tumor confined to the testis
Stage II	Infradiaphragmatic nodal involvement
IIA	greatest dimension of involved nodes less than 2 cm
IIB	greatest dimension of involved nodes 2 cm or more but less than 5 cm
IIC	greatest dimension of involved nodes 5 cm or more but less than 10 cm
IID	greatest dimension of involved nodes 10 cm or more
Stage III	Supraclavicular or mediastinal involvement
Stage IV	Extranodal metastases

### G. Serum Markers

The protocol emphasizes the importance of relevant clinical information in the pathologic evaluation of specimens. Serum marker studies play a key role in the clinical management of patients with testicular germ cell tumors.<sup>26-28</sup> The occurrence of elevated serum levels of alpha-fetoprotein (AFP) or the beta subunit of human chorionic gonadotropin (b-hCG) may indicate the need for additional sections of certain specimens if the initial findings do not account for such elevations. Information regarding pre-orchietomy serum marker status (lactate dehydrogenase [LDH], AFP, and b-hCG) is also important in the "S" categorization of the tumor for stage groupings. Post-orchietomy serum markers are important for the assignment of stage IS only.

### Anatomic Stage/Prognostic Groups

Group	T	N	M	S
Stage 0	pTis	N0	M0	S0
Stage I	pT1-4	N0	M0	SX
Stage IA	pT1	N0	M0	S0
Stage IB	pT2	N0	M0	S0
	pT3	N0	M0	S0
	pT4	N0	M0	S0
Stage IS	Any pT/TX	N0	M0	S1-3 (measured post-orchietomy)
Stage II	Any pT/TX	N1,N2,N3	M0	SX
Stage IIA	Any pT/TX	N1	M0	S0
	Any pT/TX	N1	M0	S1
Stage IIB	Any pT/TX	N2	M0	S0
	Any pT/TX	N2	M0	S1
Stage IIC	Any pT/TX	N3	M0	S0
	Any pT/TX	N3	M0	S1
Stage III	Any pT/TX	Any N	M1	SX
Stage IIIA	Any pT/TX	Any N	M1a	S0
	Any pT/TX	Any N	M1a	S1
Stage IIIB	Any pT/TX	N1,N2,N3	M0	S2
	Any pT/TX	Any N	M1a	S2
Stage IIIC	Any pT/TX	N1,N2,N3	M0	S3
	Any pT/TX	Any N	M1a	S3
	Any T	Any N	M1b	Any S

**Prognostic Factors**

Serum Tumor Markers (S)

SX Serum marker studies not available or performed

S0 Serum marker study levels within normal limits

	<u>LDH</u>		<u>HCG (mIU/mL)</u>		<u>AFP (ng/mL)</u>
S1	<1.5 X N <sup>#</sup>	and	<5,000	and	<1,000
S2	1.5-10 X N	or	5,000-50,000	or	1,000-10,000
S3	>10 X N	or	>50,000	or	>10,000

<sup>#</sup> N indicates the upper limit of normal for the LDH assay.

The Serum Tumor Markers (S) category comprises the following:

- Alpha fetoprotein (AFP) – half-life 5 to 7 days
- Human chorionic gonadotropin (hCG) – half-life 1 to 3 days
- Lactate dehydrogenase (LDH)

**H. Additional Pathologic Findings**

Important findings include Leydig cell-hyperplasia, which may be correlated with b-hCG elevation; scarring, the presence of hemosiderin-laden macrophages, and intratubular calcification, which may indicate regression of a tumor; testicular atrophy; and abnormal testicular development (eg, dysgenesis or androgen-insensitivity syndrome).<sup>29,30</sup>

**I. Metastatic Tumor**

Often the most important distinction in patients with metastatic testicular germ cell tumor following initial chemotherapy is the differentiation of metastatic residual teratoma from nonteratomatous types of germ cell tumor. Pure teratomatous metastasis is generally treated by surgical excision alone, whereas patients who have other residual germ cell tumor components are usually treated with additional chemotherapy.

**References**

1. Lawrence WD, Young RH, Scully RE. Sex cord-stromal tumors. In: Talerman A, Roth LM, eds. *Pathology of the Testis and Its Adnexa*. New York, NY: Churchill Livingstone; 1986: 67-92.
2. Proppe KH, Scully RE. Large-cell calcifying Sertoli cell tumor of the testis. *Am J Clin Pathol*. 1980;74:607-619.
3. Young RH, Talerman A. Testicular tumors other than germ cell tumors. *Semin Diagn Pathol*. 1987;4:342-360.
4. Kim I, Young RH, Scully RE. Leydig cell tumors of the testis: a clinicopathological analysis of 40 cases and review of the literature. *Am J Surg Pathol*. 1985;9:177-192.
5. Mostofi FK, Price EBJ. *Tumors of the Male Genital System: Atlas of Tumor Pathology*. 2<sup>nd</sup> series. Fascicle 8. Washington DC: Armed Forces Institute of Pathology; 1973.
6. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. *World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*. Lyon, France: IARC Press; 2004.
7. Mostofi FK, Spaander P, Grigor K, Parkinson CM, Skakkebaek NE, Oliver RT. Consensus on pathological classifications of testicular tumours. *Prog Clin Biol Res*. 1990;357:267-276.
8. Young RH, Scully RE. *Testicular Tumors*. Chicago, IL: ASCP Press; 1990.
9. Ulbright TM. Testicular and paratesticular tumors. In: Mills SE, ed. *Sternberg's Diagnostic Surgical Pathology*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:2167-2232.
10. Ulbright TM, Amin MB, Young RH. *Tumors of the Testis, Adnexa, Spermatic Cord, and Scrotum*. Third Series. Fascicle 25. Washington, DC: Armed Forces Institute of Pathology; 1999.
11. Ro JY, Dexeus FH, El-Naggar A, Ayala AG. Testicular germ cell tumors: clinically relevant pathologic findings. *Pathol Annu*. 1991;26:59-87.

12. Ferry JA, Harris NL, Young RH, Coen J, Zietman A, Scully RE. Malignant lymphoma of the testis, epididymis, and spermatic cord: a clinicopathologic study of 69 cases with immunophenotypic analysis. *Am J Surg Pathol*. 1994;18:376-390.
13. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. *J Clin Oncol*. 2002;20:4448-52.
14. Dry SM, Renshaw AA. Extratesticular extension of germ cell tumors preferentially occurs at the hilum. *Am J Clin Pathol*. 1999;111:534-8.
15. Jacobsen GK, Rorth M, Osterlind K, et al. Histopathological features in stage I non-seminomatous testicular germ cell tumours correlated to relapse: Danish Testicular Cancer Study Group. *APMIS*. 1990;98:377-382.
16. Marks LB, Rutgers JL, Shipley WU, et al. Testicular seminoma: clinical and pathological features that may predict para-aortic lymph node metastasis. *J Urol*. 1990;143:524-527.
17. Hoeltl W, Pont J, Kosak D, Honez N, Marberger M. Treatment decision for stage I non-seminomatous germ cell tumours based on the risk factor "vascular invasion." *Br J Urol*. 1992;69:83-87.
18. Sesterhenn IA, Weiss RB, Mostofi FK, et al. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. *J Clin Oncol*. 1992;10:69-78.
19. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. *Br J Cancer*. 1992;65:775-778.
20. Sturgeon JF, Jewett MA, Alison RE, et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. *J Clin Oncol*. 1992;10:564-568.
21. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. *Cancer Res*. 1994;54:362-364.
22. Edge SB, Byrd DR, Carducci MA, Compton CC, eds. *AJCC Cancer Staging Manual*. 7th ed. New York, NY: Springer; 2009.
23. Sobin LH, Gospodarowicz M, Wittekind Ch, eds. *UICC TNM Classification of Malignant Tumours*. 7th ed. New York, NY: Wiley-Liss; in press.
24. Thomas G, Jones W, VanOosterom A, Kawai T. Consensus statement on the investigation and management of testicular seminoma 1989. *Prog Clin Biol Res*. 1990;357:285-294.
25. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. *Eur J Cancer*. 1993;29A:1931-1934.
26. Chisolm GG. Tumour markers in testicular tumours. *Prog Clin Biol Res*. 1985;203:81-91.
27. Javadpour N. Tumor markers in testicular cancer: an update. *Prog Clin Biol Res*. 1985;203:141-154.
28. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. *J Clin Oncol*. 1991;9:818-826.
29. Rutgers JL, Scully RE. Pathology of the testis in intersex syndromes. *Semin Diagn Pathol*. 1987;4:275-291.
30. Wallace TM, Levin HS. Mixed gonadal dysgenesis: a review of 15 patients reporting single cases of malignant intratubular germ cell neoplasia of the testis, endometrial adenocarcinoma, and a complex vascular anomaly. *Arch Pathol Lab Med*. 1990;114:679-688.